Literature DB >> 28405904

Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Agata Buonacera1, Benedetta Stancanelli1, Lorenzo Malatino2.   

Abstract

Some tumors are a relatively rare and amendable cause of hypertension, often associated with a higher cardiovascular morbidity and mortality, as compared with that of both general population and patients with essential hypertension. This worse prognosis is not entirely related to blood pressure increase, because the release of substances from the tumor can directly influence blood pressure behavior. Diagnostic approach is challenging and needs a deep knowledge of the different neuro-hormonal and genetic mechanisms determining blood pressure increase. Surgical tumor removal can, but not always, cause blood pressure normalization, depending on how early was tumor detection, since a long-standing history of hypertension is often associated with a much weaker effect on blood pressure. Moreover, target organ damage can be affected by the substances themselves released by the tumors as well as by tumor removal. In this review we consider the phenotype and genetic features of patients with tumor-induced hypertension and focus on their diagnostic work-up.

Entities:  

Keywords:  Endocrine hypertension; Neuroendocrine tumors; Secondary hypertension; Tumor-induced hypertension

Mesh:

Substances:

Year:  2017        PMID: 28405904     DOI: 10.1007/s40292-017-0200-9

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  79 in total

1.  Left ventricular changes in primary aldosteronism.

Authors:  Gian Paolo Rossi; Maurizio Cesari; Achille C Pessina
Journal:  Am J Hypertens       Date:  2003-01       Impact factor: 2.689

2.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

3.  The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma.

Authors:  Gian Paolo Rossi; Marlena Barisa; Anna Belfiore; Giovambattista Desideri; Claudio Ferri; Claudio Letizia; Mauro Maccario; Alberto Morganti; Gaetana Palumbo; Anna Patalano; Elisabetta Roman; Teresa M Seccia; Achille C Pessina; Franco Mantero
Journal:  J Hypertens       Date:  2010-09       Impact factor: 4.844

4.  Role for adrenal venous sampling in primary aldosteronism.

Authors:  William F Young; Anthony W Stanson; Geoffrey B Thompson; Clive S Grant; David R Farley; Jon A van Heerden
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

5.  The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism.

Authors:  Gian Paolo Rossi; Marlena Barisa; Bruno Allolio; Richard J Auchus; Laurence Amar; Debbie Cohen; Christoph Degenhart; Jaap Deinum; Evelyn Fischer; Richard Gordon; Ralph Kickuth; Gregory Kline; Andre Lacroix; Steven Magill; Diego Miotto; Mitsuhide Naruse; Tetsuo Nishikawa; Masao Omura; Eduardo Pimenta; Pierre-François Plouin; Marcus Quinkler; Martin Reincke; Ermanno Rossi; Lars Christian Rump; Fumitoshi Satoh; Leo Schultze Kool; Teresa Maria Seccia; Michael Stowasser; Akiyo Tanabe; Scott Trerotola; Oliver Vonend; Jiri Widimsky; Kwan-Dun Wu; Vin-Cent Wu; Achille Cesare Pessina
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

6.  The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics.

Authors:  Elena Valassi; Alicia Santos; Maria Yaneva; Miklós Tóth; Christian J Strasburger; Philippe Chanson; John A H Wass; Olivier Chabre; Marija Pfeifer; Richard A Feelders; Stylianos Tsagarakis; Peter J Trainer; Holger Franz; Kathrin Zopf; Sabina Zacharieva; Steven W J Lamberts; Antoine Tabarin; Susan M Webb
Journal:  Eur J Endocrinol       Date:  2011-06-29       Impact factor: 6.664

7.  Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.

Authors:  G Eisenhofer; M M Walther; T T Huynh; S T Li; S R Bornstein; A Vortmeyer; M Mannelli; D S Goldstein; W M Linehan; J W Lenders; K Pacak
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Authors:  Matthew H Kulke; Dieter Hörsch; Martyn E Caplin; Lowell B Anthony; Emily Bergsland; Kjell Öberg; Staffan Welin; Richard R P Warner; Catherine Lombard-Bohas; Pamela L Kunz; Enrique Grande; Juan W Valle; Douglas Fleming; Pablo Lapuerta; Phillip Banks; Shanna Jackson; Brian Zambrowicz; Arthur T Sands; Marianne Pavel
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

9.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

Review 10.  Cushing's Syndrome.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

View more
  1 in total

1.  Grand Challenge in Adrenal Endocrinology: Is the Legacy of the Past a Challenge for the Future of Precision Medicine?

Authors:  Iacopo Chiodini; Luigi Gennari
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-03       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.